Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

REHOVOT, Israel and HOBOKEN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today highlighted results of an Investigator-Initiated Study recently presented at the 2026 International Society for Heart and Lung Transplant (ISHLT) annual meeting, held in Toronto, Canada. The study results were presented by Dr. Daniel Calabrese, MD, Associate Professor of Medicine at the UCSF Lung Transplant Program. The study is part of a comprehensive post-marketing research program aimed at generating key data in support of the benefits of CYTOGAM^®, the Company’s Cytomegalovirus Immune Globulin (CMVIG), in the management of cytomegalovirus (CMV) in solid organ transplantation.